Behandlingsregimerne for flere proteasehæmmere, som er subjekt for denne interaktion, kræver samtidig administration af lavdosis ritonavir (“ boosting ”) for at øge plasmakoncentrationerne og optimere den antivirale virkning.
Treatment paradigms for several protease inhibitors, which are subject to this interaction, require the co-administration of low-dose ritonavir (‘boosting’) in order to enhance plasma levels and optimise antiviral efficacy.